HFHiroyuki Fujita

Hiroyuki Fujita

*This is an algorithmically generated author record based on publicly available information.

Hiroyuki Fujita has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Yoshiaki Ishigatsubo

    Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    8 shared publications
  • Heiwa Kanamori

    Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    6 shared publications
  • Sachiya Takemura

    G Department of Internal Medicine , Yokohama Ekisaikai Hospital , Yokohama , Japan

    6 shared publications
  • Shin Fujisawa

    E Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan

    6 shared publications
  • Hideyuki Koharazawa

    H Department of Hematology , Shizuoka Red Cross Hospital , Shizuoka , Japan

    5 shared publications
  • Jun Taguchi

    H Department of Hematology , Shizuoka Red Cross Hospital , Shizuoka , Japan

    4 shared publications

Latest Publications

  • The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma

    by Naoto Tomita, Taisei Suzuki, Kazuho Miyashita, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, et al.

    We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p < 0.0001). When the patients were divided by age (≤60 years and >60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0–1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.


  • Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy

    by Yusuke Moriyama, Nobuyuki Horita, Makoto Kudo, Masaharu Shinkai, Hiroyuki Fujita, Takeharu Yamanaka, Yoshiaki Ishigatsubo, Takeshi Kaneko

    Both neutrophils and monocytes are differentiated from a common progenitor, a granulocyte macrophage colony forming cell, which can provide good explanation for the association between ANC and AMC nadirs. We would like to recommend physicians to observe the AMC nadir to predict the timing and severity of the ANC nadir.


    • 1 December 2012
      • Vol. 53  (12) , 2025-8

    [POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy].

    by Shiro Matsuura, Eriko Ogusa, Jun Taguchi, Noboru Imai, Hiroyuki Fujita, Naoto Tomita, Yoshiaki Ishigatsubo, Shin Fujisawa

    A 60-year-old male with POEMS syndrome received lenalidomide and high-dose dexamethasone combination therapy as an initial treatment, with no severe adverse events occurring during the treatment. Two cycles of the therapy led to significantly decreased serum VEGF level, and IgA-λ type M-protein was not detected by immunofixation electrophoresis. We next performed autologous stem cell transplantation, without severe complications such as engraftment syndrome. He improved enough to walk independently and now is being followed up without treatment. This case suggests that lenalidomide-dexamethasone therapy is highly effective and can be a good option for pre-transplant treatment for POEMS syndrome.


  • Open Access

    BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay

    by Takaaki Ono, Shuichi Miyawaki, Fumihiko Kimura, Heiwa Kanamori, Shigeki Ohtake, Kunio Kitamura, Hiroyuki Fujita, Isamu Sugiura, Kensuke Usuki, Nobuhiko Emi, et al.


    • 1 December 2010
      • Vol. 51  (12) , 1756-61

    [ABVD chemotherapy for Hodgkin lymphoma at a single institute].

    by Rika Ohshima, Shigeki Motomura, Chizuko Hashimoto, Takuya Miyazaki, Satomi Ito, Hirotaka Takasaki, Rie Hyo, Hideyuki Koharazawa, Sachiya Takemura, Etsuko Yamazaki, et al.

    Fifty-eight newly diagnosed patients with Hodgkin lymphoma were treated with ABVD chemotherapy at Yokohama City University Hematology group from October 1996 to June 2005. The median age of patients age was 41 years old and ranged from 15 to 75. Thirty-eight patients were in the early stage and 20 patients were in the advanced stage. Patients in the early stage received 3 cycles of ABVD chemotherapy and involved-field radiation therapy, while those in the advanced stage received 6 cycles of ABVD chemotherapy. The overall response rate in patients was 100% (CR 87%, PR 13%) in the early stage and 95% in the advanced stage. With a median follow-up of 44 months, the 3-year progression-free survival and overall survival were 89% and 95% in the early stage, and 70% and 81% in the advanced stage, respectively. The results of this study were similar to those previously reported in Western countries.

    • 1 January 2010
      • Vol. 51  (1) , 69-73

    [Usefulness of serum plasminogen activator inhibitor-1 for diagnosis and monitoring of late-onset sinusoidal obstruction syndrome after allogeneic stem cell transplantation].

    by Satomi Ito, Jun Taguchi, Jun Kato, Aya Nakaya, Takayoshi Tachibana, Sachiya Takemura, Ayumi Sano, Masahiko Ohata, Yoshiaki Ishigatsubo, Hiroyuki Fujita

    Sinusoidal obstruction syndrome (SOS) was originally defined as a clinical syndrome occurring by three weeks after transplantation; however, it occurs even after three or more weeks, and such cases are called late-onset SOS. We report here a case of late-onset SOS. The patient was a 17-year-old male with acute myeloid leukemia in second complete remission. He received a preparative regimen including busulfan followed by allo-peripheral blood stem cell transplantation from an HLA-matched sibling donor. On day 28 after transplantation, he developed hepatomegaly with pain. On day 33 PAI-1 level was increased. Two days later ascites developed, leading to a diagnosis of late-onset SOS. The symptoms improved with conservative therapy and the level of PAI-1 was normalized. When hepatic impairment appears three or more weeks after transplantation, late-onset SOS should be considered. PAI-1 is a useful marker for the diagnosis and follow up of late-onset SOS.

  • Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group

    by Hiroyuki Fujita, Minoru Yoshida, Katsuhiro Miura, Tetsuaki Sano, Katsuyuki Kito, Masatomo Takahashi, Kazuyuki Shigeno, Yoshinobu Kanda, Nobu Akiyama, Naoko Hatsumi, et al.

    Guidelines for the management of febrile neutropenia (FN), deep fungal infection or use of granulocyte colony-stimulating factor (G-CSF) published in the US and Europe cannot be directly applied in other countries. In this study, we undertook a questionnaire survey of member institutions of the Japan Adult Leukemia Study Group to investigate the status of, and problems with, the management of infectious complications in patients with acute leukemia. The questionnaire consisted of 52 multiple-choice questions covering therapeutic environment, antibacterial, and antifungal prophylaxis, empirical therapy (ET) for FN, and use of G-CSF. The results were compared to a previous survey performed in 2001. Usable responses were received from 134 of 184 (71.7%) institutions. With regard to antibacterial prophylaxis, fluoroquinolones and sulfamethoxazole-trimethoprim were most commonly used. Regarding antifungal prophylaxis, the most frequently used agent was fluconazole, followed by itraconazole. In ET for FN, monotherapy with cephems or carbapenems accounted for almost all of the responses. Most respondents indicated that they used micafungin (MCFG) in ET. Prophylactic use of G-CSF during remission induction therapy in acute myeloid leukemia was reported by only 4% of respondents. Strategies for antibacterial and antifungal prophylaxis or treatment of FN should be reviewed and updated as needed.


    • 1 January 2008
      • Vol. 35  (1) , 87-91

    [Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation].

    by Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Hiroyuki Fujita, Masatsugu Tanaka, Maki Hagihara, Hideyuki Koharazawa, Takuya Miyazaki, Naoto Tomita, Heiwa Kanamori, et al.

    We retrospectively investigated the hematopoietic cell transplantation-specific comorbidity index(HCT-CI)to predict non relapse mortality. Of 127 patients who underwent transplantation between January 2000 and December 2003 with conditioning consisting of total body irradiation, cyclophosphamide and thiotepa, HCT-CI scores were obtained for 83 patients. Median age was 42 years. The sources of stem cells included HLA-identical bone marrow or peripheral blood from sibling(30), HLA-matched bone marrow from unrelated donors(45), and HLA-mismatched bone marrow or peripheral blood from family donors(8). Hematological disease was divided into two groups, standard risk(47)and high risk(36). Standard risk indicates acute leukemia in first or second remission and chronic myelocytic leukemia in first chronic phase, while high risk indicates all other diagnoses. There were 45 patients with moderate or severe pulmonary comorbidities. 55 patients with HCT-CI scores of 2 or less had higher 2-year overall survival than 28 patients with HCT-CI scores of 3 or more(65% vs. 36%, p=0.0009). Although the non relapse mortality rate was not different, HCT-CI scores were a more useful indicator to predict survival in high risk patients than in standard risk patients. Prospective evaluation is warranted to clarify the usefulness of HCT-CI.


    • 1 December 2007
      • Vol. 48  (12) , 1563-6

    [Systemic neurolymphomatosis complicated in diffuse large B-cell lymphoma].

    by Takayoshi Tachibana, Naoto Tomita, Tomomi Ueda, Jun Katoh, Sachiya Takemura, Jun Taguchi, Yoji Suzuki, Masao Kasahara, Yoshiaki Ishigatsubo, Hiroyuki Fujita

    A 73-year-old woman was diagnosed with diffuse large B-cell lymphoma of the uterus (Stage IVB). After 3 courses of CHOP therapy, right abducens nerve paralysis appeared and was diagnosed as central nervous system infiltration with lymphoma cells. Although partial remission was obtained by chemotherapy with methotrexate, numbness and muscle weakness of all four limbs appeared asymmetrically and progressed subacutely. Nerve conduction velocity examination revealed mononeuritis multiplex, but we could not reach a final diagnosis. Steroid pulse therapy, chemotherapy including high-dose methotrexate, and radiation therapy were ineffective. On autopsy, histological examination of the peripheral nerves revealed systemic neurolymphomatosis.


    • 1 May 2007
      • Vol. 48  (5) , 391-6

    [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].

    by Takuya Miyazaki, Takashi Obana, Hirotaka Takasaki, Masatsugu Tanaka, Satoshi Yamaji, Katsumichi Fujimaki, Hiroyuki Fujita, Heiwa Kanamori, Yoshiaki Ishigatsubo

    It has been reported in the Western literature that patients with chronic renal disease have developed anti-erythropoietin (EPO) antibody-related pure red cell aplasia (PRCA). To investigate the incidence of anti-EPO antibody-related PRCA in Japan, we designed a questionnaire survey based on previous reports of patients who had PRCA during treatment with EPO. Thirteen of 17 patients were evaluated in this study. In all 13 patients, EPO delivery was via injection, 9 subcutaneously, 2 intravenously and 2 with a combination of the 2 methods. Three of 4 patients treated with subcutaneous EPO administration were positive for anti-EPO antibodies, but all patients treated by intravenous injection were negative. The EPO was stopped in 8 patients after the onset of PRCA, and immunosuppressive therapy with prednisolone and/or cyclosporine was administered in 12 patients. An improvement in PRCA was obtained in 12 patients. It was suspected that previous reports in Japan may have included both anti-EPO antibody-associated PRCA and incidental cases. Furthermore, subcutaneous administration of EPO may effect the production of anti-EPO antibodies.